Zacks: Analysts Anticipate Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Post Earnings of -$1.13 Per Share
Analysts expect that Theravance Biopharma, Inc. (NASDAQ:TBPH) will announce ($1.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Theravance Biopharma’s earnings. The lowest EPS estimate is ($1.18) and the highest is ($1.07). Theravance Biopharma posted earnings per share of ($1.06) in the same quarter last year, which indicates a negative year-over-year growth rate of 6.6%. The company is scheduled to announce its next quarterly earnings report on Monday, August 14th.
According to Zacks, analysts expect that Theravance Biopharma will report full-year earnings of ($4.56) per share for the current financial year, with EPS estimates ranging from ($4.90) to ($4.34). For the next financial year, analysts expect that the firm will report earnings of ($3.85) per share, with EPS estimates ranging from ($4.01) to ($3.70). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.14) by $0.13. The company had revenue of $3.09 million during the quarter, compared to analysts’ expectations of $5.07 million. Theravance Biopharma had a negative return on equity of 67.69% and a negative net margin of 641.67%.
A number of research analysts have commented on TBPH shares. Cantor Fitzgerald started coverage on shares of Theravance Biopharma in a research report on Friday, June 16th. They issued an “overweight” rating and a $55.00 target price on the stock. ValuEngine raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $42.00 target price on shares of Theravance Biopharma in a research report on Wednesday, March 22nd. Leerink Swann set a $47.00 target price on shares of Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, May 10th. Finally, Needham & Company LLC upped their target price on shares of Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, May 11th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $41.13.
Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its stake in shares of Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 3,407 shares during the period. Aperio Group LLC acquired a new stake in shares of Theravance Biopharma during the second quarter worth about $205,000. Harvest Management LLC acquired a new stake in shares of Theravance Biopharma during the first quarter worth about $228,000. OMERS ADMINISTRATION Corp raised its stake in shares of Theravance Biopharma by 31.9% in the first quarter. OMERS ADMINISTRATION Corp now owns 9,500 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 2,300 shares during the period. Finally, Principal Financial Group Inc. acquired a new stake in shares of Theravance Biopharma during the first quarter worth about $420,000. Institutional investors own 84.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Post Earnings of -$1.13 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/20/zacks-analysts-anticipate-theravance-biopharma-inc-nasdaqtbph-will-post-earnings-of-1-13-per-share.html.
Theravance Biopharma (NASDAQ TBPH) traded up 2.75% on Thursday, reaching $37.78. 482,466 shares of the company traded hands. Theravance Biopharma has a 1-year low of $22.00 and a 1-year high of $43.44. The stock has a 50 day moving average of $39.17 and a 200-day moving average of $35.61. The stock’s market capitalization is $2.02 billion.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.